2023 News Releases
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
LOS ANGELES, Calif., March 14, 2023 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a
biopharmaceutical company, announced that the results of the Phase II TBCRC041 randomized clinical trial
of alisertib alone or in combination with fulvestrant in patients with endocrine-resistant advanced breast
cancer have been published online in JAMA Oncology. Alisertib is an adenosine triphosphate–competitive
and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly
proliferating tumor cells that are dependent on aurora kinase A.
The Phase II randomized clinical trial was conducted through the Translational Breast Cancer Research
Consortium. The trial enrolled postmenopausal women with endocrine-resistant, HER2–negative metastatic
breast cancer who were previously treated with fulvestrant. For the 91 evaluable patients, baseline
characteristics were well-balanced between the two arms of the trial; however, more patients in the alisertib
plus fulvestrant arm had been previously treated with chemotherapy in the metastatic setting (47.8% in the
alisertib alone arm, 68.9% in the alisertib plus fulvestrant arm). 100% of the patients in each arm of the trial
were previously treated with CDK 4/6 inhibitors. 37% of the patients in the alisertib alone arm and 57.8% of
patients in the alisertib plus fulvestrant arm were previously treated with everolimus.
The efficacy results from the trial showed that for the 46 evaluable patients in the alisertib alone arm of the
trial nine partial responses were seen, resulting in an overall response rate of 19.6%. The median duration of
response was 15.1 months, and the 24-week clinical benefit rate was 41.3%. The median progression-free
survival (PFS) was estimated to be 5.6 months. For the 45 evaluable patients in the alisertib plus fulvestrant
arm of the trial, nine patients experienced a response, resulting in an overall response rate of 20.0%. These
responses consisted of one patient with a complete response and 8 patients with partial responses. The
median duration of response was 8.5 months, and the 24-week clinical benefit rate was 28.9%. The
estimated median PFS was 5.4 months.
In the alisertib alone arm of the trial, the most common grade 3 or higher adverse events were neutropenia
(43.4%), leukopenia (17.4%), and anemia (19.6%). In the alisertib plus fulvestrant arm of the trial, the most
common grade 3 or higher adverse events were neutropenia (42.2%), leukopenia (31.1%), lymphopenia
(15.6%), fatigue (11.1%), and anemia (8.9%).
“Although there have been new drugs approved for the treatment of ER-positive HER2-negative metastatic
breast cancer, there continues to be a need for new drugs and drugs that specifically address patients who
have been previously treated with CDK 4/6 inhibitors,” said Tufia C. Haddad, MD, Associate Professor of
Oncology at the Mayo Clinic College of Medicine and co-leader of Platform and Digital Innovation, Mayo
Clinic Comprehensive Cancer Center. “This Phase II randomized clinical trial demonstrated that alisertib is
among the first investigational targeted therapies demonstrating promising clinical activity and a tolerable
safety profile in the setting of endocrine and CDK 4/6 inhibitor resistant metastatic breast cancer. We look
forward to the continued development of alisertib in this patient population.”
“We are very pleased with the results from the TBCRC041 trial demonstrating the efficacy of alisertib in
patients with ER-positive HER2-negative metastatic breast cancer. Alisertib’s unique mechanism of action
is well suited to address the mechanisms of CDK 4/6 resistance that are targetable with an aurora kinase
inhibitor,” said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. “We greatly
look forward to advancing alisertib into additional clinical trials for ER-positive HER2-negative breast
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and
commercialization of innovative products to enhance cancer care. Puma in-licensed the global development
and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant
treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant
trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In
February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the
treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two
or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing
authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients
with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less
than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered
trademark of Puma Biotechnology, Inc.
In September 2022, Puma entered into an exclusive license agreement for the development and
commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor
of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small
cell lung cancer and breast cancer.
Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
David Schull, Russo Partners, +1 212 845 4200
# # # # #
Back to 2023 News Releases
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024